Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Prepaid Assets: 2016-2025

Historic Prepaid Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $7.0 million.

  • Akebia Therapeutics' Prepaid Assets fell 47.72% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 47.72%. This contributed to the annual value of $11.3 million for FY2024, which is 43.93% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Prepaid Assets stood at $7.0 million, which was down 10.29% from $7.8 million recorded in Q2 2025.
  • Akebia Therapeutics' Prepaid Assets' 5-year high stood at $42.1 million during Q2 2022, with a 5-year trough of $7.0 million in Q3 2025.
  • Over the past 3 years, Akebia Therapeutics' median Prepaid Assets value was $18.8 million (recorded in 2024), while the average stood at $16.2 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Prepaid Assets soared by 337.11% in 2021, and later crashed by 58.69% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Prepaid Assets stood at $33.1 million in 2021, then decreased by 0.83% to $32.9 million in 2022, then tumbled by 38.40% to $20.2 million in 2023, then slumped by 43.93% to $11.3 million in 2024, then plummeted by 47.72% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $7.8 million for Q2 2025, and $9.1 million during Q1 2025.